title: [Telemedicine and fibrinolysis in Franche-Comté].
abstract: BACKGROUND
  The aim of our study was to compare the efficacy and safety of intravenous thrombolysis of cerebral ischemia as it has been established in a distant hospital (DH) through telemedicine tools or in neurovascular unit of the University Hospital of Besançon.
  
  
  METHODS
  Our work was conducted retrospectively at the University Hospital of Besançon from 1 January 2003 to December 31, 2009.
  
  
  RESULTS
  Fibrinolysis was introduced at the university hospital in 98/161 patients (61%) and a DH in remote 63/161 patients (39%). A favorable neurological outcome (Rankin 0/1) was observed in 27/98 patients (27.5%) treated at University Hospital and in 25/63 (39.5%) patients in a DH. There was no significant difference between the two subgroups. Symptomatic hemorrhagic transformation occurred in 5/98 (5%) patients treated at University Hospital and in 1/63 (1.5%) patients treated in DH. There was no significant difference between the two subgroups.
  
  
  CONCLUSIONS
  Our study shows that fibrinolysis remotely using the tools of telemedicine has, from 2003 to 2009, in Franche-Comté deal effectively and without risk of a significant proportion of patients.
authors: Service de neurologie 2 neurovasculaire et urgences neurologiques, CHU de Besançon, 3 boulevard Alexandre-Fleming, Besançon cedex, France. rallibert@hotmail.fr
authors: R
authors: R
authors: Allibert
authors: F
authors: F
authors: Ziegler
authors: M
authors: M
authors: Bataillard
authors: C
authors: C
authors: Gomes
authors: A
authors: A
authors: Jary
authors: T
authors: T
authors: Moulin
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002545:Brain Ischemia / Q000188:drug therapy / Q000453:epidemiology; D002543:Cerebral Hemorrhage / Q000453:epidemiology / Q000209:etiology; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D005602:France / Q000453:epidemiology; D006785:Hospitals, University; D006801:Humans; D008297:Male; D008875:Middle Aged; D009422:Nervous System Diseases / Q000209:etiology / Q000628:therapy; D061214:Patient Safety; D010360:Patient Transfer; D012189:Retrospective Studies; D020521:Stroke / Q000188:drug therapy; D017216:Telemedicine / Q000379:methods*; D015912:Thrombolytic Therapy / Q000009:adverse effects / Q000379:methods*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator